Portland, OR -- (SBWIRE) -- 02/20/2018 -- Intravenous immunoglobulin (IVIG) is used in the treatment of deficiency disorders such as hypogammaglobulinemia, Kawasaki disease, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Globally, the rise in immunoglobulin deficiency and the associated disorders drive the use of IVIG in clinical settings. GAMUNEX-C, Flebogamma DIF 5% & 10%, Gammaplex, and Kiovig are the key regulated products approved for use in therapy settings. There are several products that are available in market as "off-label" products, including Gammagard Liquid intravenous, Gammagard S/D intravenous, and Bivigam intravenous.

Get Report Sample @ https://www.alliedmarketresearch.com/request-sample/325

Recently, a paradigm shift has been observed in the development of sub-cutaneous immunoglobulin therapy, which limits the focus on development of intravenous immunoglobulin-based products. Sub-cutaneous immunoglobulin formulations offer additional advantageous for patients in terms of ease of administration resulting in their increasing use in home settings. The IVIG market is an oligopolistic market, dominated by Grifols, CSL Behring, Baxter International, and Octapharma. Further, these companies have a strong hold on blood fractionation industry, and hence play a key role in determining the cost of blood product commodities such as albumin, fibrinogen, and other plasma entities.

Top Investment Pockets:

Hypogammaglobulinemia, CIDP, and PID are the most lucrative application segments of the global IVIG market, which collectively accounted for ~50% of the overall market share in 2015. Emergence of potentially advanced technologies, such as recombinant biotechnology, along with the increase in acceptance of IVIG therapies, significantly impacts the IVIG market growth. Despite the high cost associated with IVIG therapy, hypogammaglobulinemia, CIDP, and immunodeficiency diseases remained the highest revenue-generating segments. The global IVIG market for hypogammaglobulinemia expected to grow with a CAGR of 6%. .

IgG replacement therapy is the most preferred treatment option for most immunodeficiency syndromes, namely X-linked, severe combined immunodeficiency, hyper-IgM, adenosine deaminase deficiency, common variable immunodeficiency (CVID), and WiskottAldrich syndrome. Key players such as CSL Ltd., Baxter International Inc., Grifols S.A., Octapharma Inc., and others focus on the development of IVIG therapies to treat various primary immunodeficiency diseases (PIDs). In accordance to the CIDP, IVIG treatment resulted in effective treatment for patients with a CIDP. Approximately, 40% of a patient's CIDP treated with IVIG needed intermittent IVIG infusions to maintain improved clinical conditions, and it is further expected to be effective throughout the treatment. The global IVIG market for CIDP was valued at $1,629 million in 2015 and is expected to reach $2,452 million by 2022, growing at a CAGR of 6%.

Buy Now (Discount on Report) https://www.alliedmarketresearch.com/checkout/910896

IVIG market (Intravenous Immunoglobulin Market) was valued at $7,861 million, and is expected to reach $12,632 million by 2022, supported by a CAGR of 7.1%. Key players in the IVIG market focus on expanding their business operations in emerging countries, with new product launches as a preferred strategy. Leading companies profiled in this report include Baxter International Inc., CSL Ltd., Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products, Inc., BDI Pharma Inc., and Bayer Healthcare.